Show simple item record

dc.contributor.authorDiez, P.
dc.contributor.authorHanna, G. G.
dc.contributor.authorAitken, K. L.
dc.contributor.authorvan As, N.
dc.contributor.authorCarver, A.
dc.contributor.authorColaco, Rovel J
dc.contributor.authorConibear, J.
dc.contributor.authorDunne, E. M.
dc.contributor.authorEaton, D. J.
dc.contributor.authorFranks, K. N.
dc.contributor.authorGood, J. S.
dc.contributor.authorHarrow, S.
dc.contributor.authorHatfield, P.
dc.contributor.authorHawkins, M. A.
dc.contributor.authorJain, S.
dc.contributor.authorMcDonald, F.
dc.contributor.authorPatel, R.
dc.contributor.authorRackley, T.
dc.contributor.authorSanghera, P.
dc.contributor.authorTree, A.
dc.contributor.authorMurray, L.
dc.date.accessioned2022-08-17T09:45:46Z
dc.date.available2022-08-17T09:45:46Z
dc.date.issued2022en
dc.identifier.citationDiez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, et al. UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clinical Oncology. 2022 May;34(5):288-300. PubMed PMID: WOS:000821121800008.en
dc.identifier.pmid35272913en
dc.identifier.doi10.1016/j.clon.2022.02.010.en
dc.identifier.urihttp://hdl.handle.net/10541/625471
dc.description.abstractThe use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus for normal tissue constraints for SABR was published in 2017, based on the existing literature at the time. The published literature regarding SABR has increased in volume over the past 5 years and multiple UK centres are currently working to develop new SABR services. A review and update of the previous consensus is therefore appropriate and timely. It is hoped that this document will provide a useful resource to facilitate safe and consistent SABR practice.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.clon.2022.02.010.en
dc.titleUK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapyen
dc.typeArticleen
dc.contributor.departmentRadiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UKen
dc.identifier.journalClinical Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record